# A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

> **NCT01119859** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 326 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Adalimumab
- **DRUG:** Placebo to tocilizumab
- **DRUG:** Placebo to adalimumab

## Key facts

- **NCT ID:** NCT01119859
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01119859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01119859, "A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01119859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*